Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Licenses IP for Thymoma Test

NEW YORK (GenomeWeb News) – Castle Biosciences said yesterday that it has licensed exclusive worldwide rights to intellectual property covering a gene expression profiling test for thymoma, rare tumors derived from the epithelial cells of the thymus gland.

The firm licensed the IP from Indiana University Research and Technology Corp., a non-profit tech transfer group associated with the university. The gene signature underlying Castle Biosciences' DecisionDx-Thymoma test was discovered by Indiana University researchers.

Friendswood, Texas-based Castle Biosciences said the test has shown that it can accurately predict metastatic risk in patients with thymoma and can accurately confirm the stage of disease at diagnosis. The firm is working with Indiana University to complete clinical validation of an independent test set and aims to have the test clinically available by the end of this quarter.

"The ability to accurately assess metastatic risk based upon the thymoma's molecular signature will enable personalizing therapeutic options and assist in deciding which patients should receive post-operative therapy," Patrick Loehrer, director of the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, said in a statement.

Financial and other terms of the license were not disclosed.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.